{"name":"Certara","slug":"certara","ticker":"CERT","exchange":"NASDAQ","domain":"certara.com","description":"Certara is a former municipality in the district of Lugano in the canton of Ticino in Switzerland. On 14 April 2013 the former municipalities of Bogno, Cadro, Carona, Certara, Cimadera, Valcolla and Sonvico merged into the municipality of Lugano.","hq":"Princeton, NJ","founded":0,"employees":"1515","ceo":"William F. Feehery","sector":"Biosimulation / Regulatory Science Software","stockPrice":5.68,"stockChange":0.06,"stockChangePercent":1.07,"marketCap":"$905M","metrics":{"revenue":418838000,"revenueGrowth":3.3,"grossMargin":61.5,"rdSpend":41040000,"netIncome":-1595000,"cash":189392000,"dividendYield":0,"peRatio":11.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Certara Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Certara reported revenue of $123.4 million for the fourth quarter and $444.8 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Certara Announces Collaboration with Pfizer to Develop AI-Powered Predictive Models","summary":"Certara partnered with Pfizer to develop AI-powered predictive models for drug development.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Certara Receives FDA Clearance for Simulations Plus","summary":"The FDA cleared Certara's Simulations Plus software for use in drug development.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxONGluMUdXeXhBWk9QdWJxNGZPTzk1R2hMVkYwbThKSkEwczNXV1d1aWZraExSN1pPSk03Q3ROTTA1NHZLclo5U0liLVFZRkRrenFKa2Y1U3JXZXVHRkxYbWliMGhXTnQyS29zT3c5dVJJdnZhdklMZE9FajBtT2JkQ0xJOFhtRlNGMGJGVldkOG52dUpFR1FGZzBYT3V6cWgxNE5SWkN1aVZXcVdzNm9TQ2pKcDJicmNlOU9WLVZEVTZOeXBiWG9wSnhR0gHPAUFVX3lxTE5IWk42N21ZalRyWGhZUFdXVmF6UDZudWphclpoUnhuUWZzbzdDSUtwcjBIX1hrLVF4S1RPc0FrT0RPbjRDaERydVM5WTVLSG5Hcm94Vk1Jb2lwTXV4aDhuX0o1Sk9SalVrMkh3Tk02bUVQWHV0Q3l3V1MtNXhKbUt4c0RtU3dPVjZWdlMzZHp2ZWxSblRDc3JYT3dMaHJOUGVYTGZ3YzJGV0dEeGtaLTB4aUNIajhPaVNRY192MThzaVppa0F3and2ek9GeVJzOA?oc=5","date":"2026-03-15","type":"regulatory","source":"simplywall.st","summary":"Assessing Certara (CERT) Valuation After FDA PBPK Milestone And New Biosimulation Software Launches - simplywall.st","headline":"Assessing Certara (CERT) Valuation After FDA PBPK Milestone And New Biosimulation Software Launches","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-09","type":"regulatory","source":"simplywall.st","summary":"How Investors Are Reacting To Certara (CERT) FDA Acceptance Of Simcyp In Place Of Clinical Trials - simplywall.st","headline":"How Investors Are Reacting To Certara (CERT) FDA Acceptance Of Simcyp In Place Of Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNOWc5OHlCRTJJV2VraThUNFNnM0QtczNlMnp0TVZYS19VbkNTTGZOQmZzOW9nZ1FoVnZOZ0dlS0R6cmJiWWsxYkgweGRVRTFkNGtUSDhhWFN5S3hNVjVOcUdDaTBMSWpVeVBOb3FCbDBoZm1ZNEZfY3VtY0dyX1FibE8xbXZ2RlBXRHR1anFDUDBLNEc5M1BBenpZTjZCZTRRbkRYUVp4cXZVSmFoY0Y5ZDhhUzhZUlE?oc=5","date":"2026-03-03","type":"regulatory","source":"Stock Titan","summary":"FDA accepts virtual-patient data so leukemia drug avoids 10 trials - Stock Titan","headline":"FDA accepts virtual-patient data so leukemia drug avoids 10 trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOX1JaNUV0cUZOM3AteDI4QVJBRnowM1A3dHlZUzc0RERhZlRtVDFCOUpqVVV2M0U4R3B1NTNIZUhZOElOaTlKUTViYmlQMHUzZmlEa0lldU1YWjZVNHV3a3FYZXhVbEtVQjJFYXFvWUFVVDlUOTBFV0J4Q1l4Qk5lNjhVak95ZHZja2dNOTA5aWFEdkhDOEpQX3NzZTNYRFJYalBPWWlrdE5jMnMzcmZVUlhpZmxGcEFyQ2x2MHVVVUVlbEpseWluUkNpM1o4dWZf?oc=5","date":"2026-03-02","type":"earnings","source":"The Globe and Mail","summary":"Certara Earnings Call: Software Strength Amid Transition - The Globe and Mail","headline":"Certara Earnings Call: Software Strength Amid Transition","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQRi0zQzkySmt2VnR6NlpsVHlXdUtGVVNWYUdhRFFDQ2pYRVU1Q0ZIbGduNVoxdmZ4MzRmeFhjOGxlR191ZUlnQlh4YmlzeFFraHlYMmFvdTlfYUpvWjdQUkg4UnotVjRqQ2xTelFNVEkybl9yR2VNODE1SzZTQ3p1NHJoTmxaazJmSlZUM2VzdlF5elBueC1NdVVVMUpnNGdWSEo3OUkzcEd0aGFBTGFjQ3dZRk4wRGY1eWZKekJB?oc=5","date":"2026-01-19","type":"pipeline","source":"AD HOC NEWS","summary":"Certara Inc EXPOSED: The Quiet Pharma Tech Power Move Wall Street Is Sleeping On - AD HOC NEWS","headline":"Certara Inc EXPOSED: The Quiet Pharma Tech Power Move Wall Street Is Sleeping On","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNbnVTbjIzTWFUWDNJLXBMUjExd2kzaXd6RXVqS3dXWkZ6ajZxOXVDWGFIRzQ5RGptR0p2b1BmbWRXMl9qY3JYZ0w5YkxlU0l2cmtoQTM0VnpnVDNieUV1RzNhU2pzdFlBMlhObkJ1dWx2SlBFLURWenRWN0pPaWwzSVJZTkdVbXV4UjBqSDFpaGZBUFpWTW95d0xtUWRyM29yS0U1ZTdOVXZxczVJOG9SU1NNVzRPWmZxVU52YzJHMmRyVkgyYnIwek9BMmtmblJmcXY0SnYyamxNMjVhT1JqeGVVcG5fd0t2cU01QmhnWnZVZWJLaTdDSjhTVQ?oc=5","date":"2026-01-05","type":"earnings","source":"FinancialContent","summary":"Certara’s Volatility: From a 23% Earnings Plunge to a $3 Million Institutional Vote of Confidence - FinancialContent","headline":"Certara’s Volatility: From a 23% Earnings Plunge to a $3 Million Institutional Vote of Confidence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQa1RZaEhUczlWd0xyNmlERDFIUXNQekp0eU5yb0xRZFJDSWJiX3NQcVU3UEJSMGRGajJCTXprYXc4ck1qUWNoMkd1bmI2Z0hqc2tjb1ZFWGgyMlRyX0ZoWTdpczkzLVY2bm5jQllUdllGNjIydTBYOHRidUdfa29MV1VB?oc=5","date":"2025-12-12","type":"pipeline","source":"Yahoo Finance","summary":"Will Certara’s (CERT) New IQVIA-Veteran CEO Reframe Its Biosimulation and AI Leadership Story? - Yahoo Finance","headline":"Will Certara’s (CERT) New IQVIA-Veteran CEO Reframe Its Biosimulation and AI Leadership Story?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPWVR2YlJBNU9xYXBhT2dNbWFjZnRCMGhubEZod1VRMkpsNkE4UkRzbTgwUU5UMFU3bVJQaEZJbFQ2U29TdEstdl9kZlQtRjJjT294WGdfYk5TeW92cGY2QVRYYmh6TTlrQUMtRjh5NFJuY2IwdldfWjFFU0J2cnh4Z0hwQ2k?oc=5","date":"2025-12-11","type":"pipeline","source":"Yahoo Finance","summary":"Certara (CERT) Valuation Check as New CEO Jon Resnick Takes Over and Outlook Is Reaffirmed - Yahoo Finance","headline":"Certara (CERT) Valuation Check as New CEO Jon Resnick Takes Over and Outlook Is Reaffirmed","sentiment":"neutral"},{"date":"2025-12-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPbWJLUC1zUDdCVXA1ZnpJTEpEZEJQaWhiWlhGUFRORVprSmtZVVNicjRzZW9WRWo0UEFkMm1GWXNCdkhfdkU1LXA0T2tFZzF1ZWJqcTdFSm1LV1JoM05lUTF3X1FxM3B1SDZVQVMxOVJjb2YtTUdWY3p5VjVIa3M2MnRjeEM2MmVUQlphVzdZZHpLWG5ta2pkQW1qeVpkM1BEM2JNVG4tNThia0ZMZVQ5UTdudG9wM3ZuR3V2dHJFR21WbW5LNTE4SUVMRjdEdw?oc=5","date":"2025-11-06","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Certara Q3 2025 sees minor earnings beat, stock drops - Investing.com","headline":"Earnings call transcript: Certara Q3 2025 sees minor earnings beat, stock drops","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQZ3RzSXpMUS15cUJyY254b2FUOEdQZHN4NG13VWZVMjhVSU9QaGJUYjVOTWdKN280SmNZZGFSc2tWTkxOek4yY09BNWxuZXpDeFptcnMyTFF6bXpjNllFY2NrNHZsSUx2TExyMEZ5bkQtM2k4Wmh4QjNsLU5ld0FqcFRUT0dNQmlCb0JhOA?oc=5","date":"2025-10-15","type":"pipeline","source":"Seeking Alpha","summary":"Why Investors Should Consider Certara Again (NASDAQ:CERT) - Seeking Alpha","headline":"Why Investors Should Consider Certara Again (NASDAQ:CERT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1FNkdyQm5ha19FRlBadzBYN0xCMXVUNDdCM3hNQndEOHdTdXlYRl9WTm0wMjlqYjZ1RzdiRmRwN0hFREdScVF0Ykp1SExzc3pHQ2xOMWhsZWFRbFE0UmNLSDRxeWFac2pMV2F3cm90WFNjMjlxYTRTdHhpUjY?oc=5","date":"2025-08-07","type":"pipeline","source":"Yahoo Finance","summary":"Certara, Inc. (CERT): A Bull Case Theory - Yahoo Finance","headline":"Certara, Inc. (CERT): A Bull Case Theory","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Dassault Systèmes","IBM","Oracle"],"therapeuticFocus":["Oncology","Cardiovascular","Rare Diseases"],"financials":{"source":"sec_edgar","revenue":418838000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":418838000,"period":"2025-12-31"},{"value":385148000,"period":"2024-12-31"},{"value":385148000,"period":"2024-12-31"},{"value":354337000,"period":"2023-12-31"},{"value":354337000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":41040000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-1595000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1556582000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":5.68,"previousClose":5.62,"fiftyTwoWeekHigh":15.38,"fiftyTwoWeekLow":5.24,"fiftyTwoWeekRange":"5.235 - 15.38","fiftyDayAverage":7,"twoHundredDayAverage":9.64,"beta":1.62,"enterpriseValue":1012746368,"forwardPE":11.4,"priceToBook":0.85,"priceToSales":2.16,"enterpriseToRevenue":2.42,"enterpriseToEbitda":10.28,"pegRatio":0,"ebitda":98474000,"ebitdaMargin":23.5,"freeCashflow":96402752,"operatingCashflow":96325000,"totalDebt":307774016,"debtToEquity":29,"currentRatio":2.05,"returnOnAssets":0.9,"returnOnEquity":-0.1,"analystRating":"2.2 - Buy","recommendationKey":"buy","numberOfAnalysts":11,"targetMeanPrice":8.99,"targetHighPrice":11,"targetLowPrice":6.35,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.7,"institutionHeldPercent":122.9,"sharesOutstanding":153325078,"floatShares":118834285,"sharesShort":23791072,"shortRatio":6.8,"shortPercentOfFloat":14.9,"epsTrailing":-0.01,"epsForward":0.5,"revenuePerShare":2.61,"bookValue":6.68,"officers":[{"age":60,"name":"Mr. Leif E. Pedersen","title":"President & Chief Commercial Officer"},{"age":52,"name":"Mr. John E. Gallagher III","title":"SVP, Principal Accounting Officer & Chief Financial Officer"},{"age":53,"name":"Dr. Robert P. Aspbury Ph.D.","title":"President of Certara Predictive Technologies"},{"age":null,"name":"Dr. Christopher  Bouton Ph.D.","title":"Chief Technology Officer"},{"age":null,"name":"Mr. Ron  DiSantis","title":"Senior Vice President of Corporate Development"},{"age":null,"name":"Ms. Sheila  Rocchio MBA","title":"Chief Marketing Officer"}],"industry":"Health Information Services","irWebsite":"","website":"https://www.certara.com","phone":"415 237 8272"}}